{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:54:09Z","timestamp":1790974449109,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The need for simple, non-invasive biomarkers for prostate cancer (PCa) diagnosis is increasing. Urinary PSA (uPSA) and Zinc (uZinc) are emerging as potential PCa risk indicators. This study aimed to develop a rapid urine test combining uPSA and uZinc, assessing its diagnostic value alone and with Standard of Care (SOC) parameters, including age, serum PSA, DRE, and multiparametric Magnetic Resonance Imaging (mpMRI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled 260 men undergoing prostate biopsy. Post-massage urine samples were analyzed using a rapid urine test combining lateral flow immunoassay (uPSA) and colorimetric dipstick assay (uZinc) with confirmatory testing via ELISA and colorimetric in vitro assay. Logistic regression models (SOC, uPSA, uZinc, Urine test [uPSA\u2009+\u2009uZinc], SOC\u2009+\u2009Urine test) and mpMRI models were tested. Diagnostic accuracy was evaluated using AUCs from ROC analysis. A decision-making algorithm targeting patients with increased PSA up to 10\u2009ng\/mL, negative DRE, and PIRADS\u2009\u2264\u20093 was proposed to assess the number of unnecessary biopsies potentially avoided with the urine test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 242 evaluable patients, 146 (59%) had PCa. The rapid Urine test provided intensity scores inversely proportional to biomarker concentration. uPSA strongly correlated with clinical stage, D\u2019Amico risk, and Gleason score, while uZinc showed a weaker trend. The Urine test reached an AUC of 0.769, which improved performance to 0.789 with SOC\u2009+\u2009Urine test (p\u2009=\u20090.0002). Combining urine markers with mpMRI yielded AUCs of 0.868 (mpMRI+Urine test) and 0.875 (mpMRI+SOC+Urine test; p\u2009&lt;\u20090.0001). The decision-making algorithm integrating urine test demonstrated that 51% of men could safely avoid biopsy, with a 13% detection rate of only low-grade PCas (ISUP\u2009&lt;\u20092) in this group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This uPSA\/uZinc urine test is a promising adjunct to current diagnostic pathways, improving accuracy in detecting clinically significant PCa while reducing unnecessary biopsies. Its integration with mpMRI and SOC parameters could refine risk assessment and personalize patient management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-025-01030-2","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T03:45:23Z","timestamp":1765165523000},"page":"385-391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A rapid urinary test for combining PSA and zinc to enhance prostate cancer diagnosis: results from a prospective study"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5425-5453","authenticated-orcid":false,"given":"Daniele","family":"Amparore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7798-6926","authenticated-orcid":false,"given":"Sabrina","family":"De Cillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9857-4130","authenticated-orcid":false,"given":"Davide","family":"Zamengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ortenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Alladio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Di Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Porpiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"1030_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur Urol. 2023;84:191\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021.","journal-title":"Eur Urol"},{"key":"1030_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"key":"1030_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.23736\/S2724-6051.22.05121-7","volume":"75","author":"M Baboudjian","year":"2023","unstructured":"Baboudjian M, Touzani A, Martini A, Diamand R, Roche JB, Lacetera V, et al. Oncological outcomes of radical prostatectomy in very high-risk patients according to STAMPEDE criteria: does local treatment alone still have a place in the era of intensified systemic therapies?. Minerva Urol Nephrol. 2023;75:124\u20136. https:\/\/doi.org\/10.23736\/S2724-6051.22.05121-7.","journal-title":"Minerva Urol Nephrol"},{"key":"1030_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41391-022-00535-4","volume":"26","author":"V Achard","year":"2023","unstructured":"Achard V, Zilli T. Prostate cancer intensity-modulated radiotherapy and long term genitourinary toxicity: an evolving therapeutic landscape. Prostate Cancer Prostatic Dis. 2023;26:1\u20132. https:\/\/doi.org\/10.1038\/s41391-022-00535-4.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1030_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.23736\/S2724-6051.22.05120-5","volume":"75","author":"S Remmers","year":"2023","unstructured":"Remmers S, Venderbos LD, Deschamps A, Dowling J, Carl EG, Roobol MJ. Sexual and urinary function in prostate cancer clinical studies and the Europa Uomo Patient Reported Outcome Study: does it match?. Minerva Urol Nephrol. 2023;75:188\u201393. https:\/\/doi.org\/10.23736\/S2724-6051.22.05120-5.","journal-title":"Minerva Urol Nephrol"},{"key":"1030_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","volume":"27","author":"SJ Freedland","year":"2024","unstructured":"Freedland SJ, Davis M, Epstein AJ, Arondekar B, Ivanova JI. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. 2024;27:327\u201333. https:\/\/doi.org\/10.1038\/s41391-023-00725-8.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1030_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"key":"1030_CR8","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","volume":"391","author":"J Hugosson","year":"2024","unstructured":"Hugosson J, Godtman RA, Wallstrom J, Axcrona U, Bergh A, Egevad L, et al. Results after four years of screening for prostate cancer with PSA and MRI. N Engl J Med. 2024;391:1083\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2406050.","journal-title":"N Engl J Med"},{"key":"1030_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2024.13806","volume":"332","author":"MR Goldstein","year":"2024","unstructured":"Goldstein MR, Mascitelli L. PSA screening and prostate cancer mortality. JAMA. 2024;332:843 https:\/\/doi.org\/10.1001\/jama.2024.13806.","journal-title":"JAMA"},{"key":"1030_CR10","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683\u2013722. https:\/\/doi.org\/10.1016\/S0140-6736(24)00651-2. Apr 27 Epub 2024 Apr 4. Erratum in: Lancet. 2024 Apr 27;403(10437):1634. 10.1016\/S0140-6736(24)00748-7.","journal-title":"Lancet"},{"key":"1030_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.23736\/S2724-6051.24.06117-2","volume":"76","author":"V Ficarra","year":"2024","unstructured":"Ficarra V, Bartoletti R, Borghesi M, Caffo O, DE Nunzio C, Falagario UG, et al. Italian Society of Urology (SIU) panel. Organized prostate cancer screening program: a proposal from the Italian Society of Urology (SIU). Minerva Urol Nephrol. 2024;76:519\u201329. https:\/\/doi.org\/10.23736\/S2724-6051.24.06117-2.","journal-title":"Minerva Urol Nephrol"},{"key":"1030_CR12","doi-asserted-by":"publisher","first-page":"530","DOI":"10.23736\/S2724-6051.24.06118-4","volume":"76","author":"V Ficarra","year":"2024","unstructured":"Ficarra V, Bartoletti R, Borghesi M, DE Nunzio C, Falagario UG, Gandaglia G, et al. Italian Society of Urology (SIU) panel. Prostate cancer diagnostic pathway in men with lower urinary tract symptoms or performing opportunistic screening: the Italian Society of Urology (SIU) position paper. Minerva Urol Nephrol. 2024;76:530\u20135. https:\/\/doi.org\/10.23736\/S2724-6051.24.06118-4.","journal-title":"Minerva Urol Nephrol"},{"key":"1030_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamaoncol.2024.0734","volume":"10","author":"T Fazekas","year":"2024","unstructured":"Fazekas T, Shim SR, Basile G, Baboudjian M, K\u00f3i T, Przydacz M, et al. Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis. JAMA Oncol. 2024;10:745\u201354. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0734.","journal-title":"JAMA Oncol"},{"key":"1030_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109071","volume":"129","author":"S Mahjoub","year":"2020","unstructured":"Mahjoub S, Baur ADJ, Lenk J, Lee CH, Hartenstein A, Rudolph MM, et al. Optimizing size thresholds for detection of clinically significant prostate cancer on MRI: peripheral zone cancers are smaller and more predictable than transition zone tumors. Eur J Radio. 2020;129:109071. https:\/\/doi.org\/10.1016\/j.ejrad.2020.109071.","journal-title":"Eur J Radio"},{"key":"1030_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.23736\/S2724-6051.23.05319-3","volume":"75","author":"F Zattoni","year":"2023","unstructured":"Zattoni F, Maggi M, Giganti F, Gandaglia G. EAU-YAU Prostate Cancer Working Party. Experience in Multiparametric magnetic resonance prior to targeted prostate biopsy: the tip of the iceberg for cancer detection?. Minerva Urol Nephrol. 2023;75:254\u20137. https:\/\/doi.org\/10.23736\/S2724-6051.23.05319-3.","journal-title":"Minerva Urol Nephrol"},{"key":"1030_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00827-x","author":"UG Falagario","year":"2024","unstructured":"Falagario UG, Pellegrino F, Fanelli A, Guzzi F, Bartoletti R, Cash H, et al. Prostate cancer detection and complications of MRI-targeted prostate biopsy using cognitive registration, software-assisted image fusion or in-bore guidance: a systematic review and meta-analysis of comparative studies. Prostate Cancer Prostatic Dis. 2024. https:\/\/doi.org\/10.1038\/s41391-024-00827-x.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1030_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2023.111255","volume":"170","author":"A Khan","year":"2024","unstructured":"Khan A, Moore CM, Minhaj Siddiqui M. Prostate MRI and image quality: the urologist\u2019s perspective. Eur J Radio. 2024;170:111255. https:\/\/doi.org\/10.1016\/j.ejrad.2023.111255.","journal-title":"Eur J Radio"},{"key":"1030_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41391-024-00840-0","volume":"28","author":"HS Robinson","year":"2025","unstructured":"Robinson HS, Lee SS, Barocas DA, Tosoian JJ. Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer. Prostate Cancer Prostatic Dis. 2025;28:45\u201355. https:\/\/doi.org\/10.1038\/s41391-024-00840-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1030_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/MOU.0000000000001188","volume":"35","author":"CH Wong","year":"2025","unstructured":"Wong CH, Ko IC, Ng CF. Liquid biomarkers in prostate cancer: recent advancements and future directions. Curr Opin Urol. 2025;35:3\u201312. https:\/\/doi.org\/10.1097\/MOU.0000000000001188.","journal-title":"Curr Opin Urol"},{"key":"1030_CR20","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41391-023-00660-8","volume":"26","author":"AE Ross","year":"2023","unstructured":"Ross AE. Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy na\u00efve men. Prostate Cancer Prostatic Dis. 2023;26:588\u201395. https:\/\/doi.org\/10.1038\/s41391-023-00660-8.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1030_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41391-020-0237-z","volume":"23","author":"R Tutrone","year":"2020","unstructured":"Tutrone R, Donovan MJ, Torkler P, Tadigotla V, McLain T, Noerholm M, et al. Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10\u2009ng\/mL. Prostate Cancer Prostatic Dis. 2020;23:607\u201314. https:\/\/doi.org\/10.1038\/s41391-020-0237-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1030_CR22","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.mam.2012.11.007","volume":"34","author":"M-C Franz","year":"2013","unstructured":"Franz M-C, Anderle P, B\u00fcrzle M, Suzuki Y, Freeman M, Hediger M, et al. Zinc transporters in prostate cancer. Mol Asp Med. 2013;34:735\u201341. https:\/\/doi.org\/10.1016\/j.mam.2012.11.007.","journal-title":"Mol Asp Med"},{"key":"1030_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1088\/0031-9155\/54\/3\/020","volume":"54","author":"M Cortesi","year":"2009","unstructured":"Cortesi M, Chechik R, Breskin A, Vartsky D, Ram\u00f3n J, Raviv G, et al. Evaluating the cancer detection and grading potential of prostatic-zinc imaging: a simulation study. Phys Med Biol. 2009;54:781\u201396. https:\/\/doi.org\/10.1088\/0031-9155\/54\/3\/020.","journal-title":"Phys Med Biol"},{"key":"1030_CR24","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.3390\/cancers14215316","volume":"14","author":"MG Maddalone","year":"2022","unstructured":"Maddalone MG, Oderda M, Mengozzi G, Gesmundo I, Novelli F, Giovarelli M, et al. Urinary zinc loss identifies prostate cancer patients. Cancers. 2022;14:5316 https:\/\/doi.org\/10.3390\/cancers14215316.","journal-title":"Cancers"},{"key":"1030_CR25","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.3390\/cancers13143570","volume":"13","author":"S Occhipinti","year":"2021","unstructured":"Occhipinti S, Mengozzi G, Oderda M, Zitella A, Molinaro L, Novelli F, et al. Low levels of urinary PSA better identify prostate cancer patients. Cancers. 2021;13:3570 https:\/\/doi.org\/10.3390\/cancers13143570.","journal-title":"Cancers"},{"key":"1030_CR26","doi-asserted-by":"publisher","first-page":"340","DOI":"10.23736\/S2724-6051.24.05783-5","volume":"76","author":"D Amparore","year":"2024","unstructured":"Amparore D, DE Cillis S, Granato S, Ortenzi M, Della Corte M, Sica M, et al. Urinary PSA-ZINC biomarker outperforms standard of care in early detection of prostate cancer. Minerva Urol Nephrol. 2024;76:340\u201350. https:\/\/doi.org\/10.23736\/S2724-6051.24.05783-5.","journal-title":"Minerva Urol Nephrol"},{"key":"1030_CR27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.eururo.2024.04.036","volume":"86","author":"P Vynckier","year":"2024","unstructured":"Vynckier P, Annemans L, Raes S, Amrouch C, Lindgren P, M\u00e1jek O, et al. Members of the PRAISE-U Consortium. Systematic review on the cost effectiveness of prostate cancer screening in Europe. Eur Urol. 2024;86:400\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.036.","journal-title":"Eur Urol"},{"key":"1030_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.23736\/S2724-6051.22.05189-8","volume":"75","author":"F Porpiglia","year":"2023","unstructured":"Porpiglia F, Checcucci E, DE Cillis S, Piramide F, Amparore D, Piana A, et al. A prospective randomized controlled trial comparing target prostate biopsy alone approach vs. target plus standard in na\u00efve patients with positive mpMRI. Minerva Urol Nephrol. 2023;75:31\u201341. https:\/\/doi.org\/10.23736\/S2724-6051.22.05189-8.","journal-title":"Minerva Urol Nephrol"},{"key":"1030_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.snb.2020.128812","volume":"325","author":"F Di Nardo","year":"2020","unstructured":"Di Nardo F, Occhipinti S, Gontero P, Cavalera S, Chiarello M, Baggiani C, Anfossi L. Detection of urinary prostate specific antigen by a lateral flow biosensor predicting repeat prostate biopsy outcome. Sens Actu B Chem. 2020;325:128812. https:\/\/doi.org\/10.1016\/j.snb.2020.128812.","journal-title":"Sens Actu B Chem"},{"key":"1030_CR30","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5. EAU Guidelines Office, Arnhem, The Netherlands. http:\/\/uroweb.org\/guidelines\/compilations-of-all-guidelines\/"},{"key":"1030_CR31","doi-asserted-by":"publisher","unstructured":"Stopka-Farooqui U, Stavrinides V, Simpson BS, Qureshi H, Carmona Echevierra LM, Pye H, et al. Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study. Prostate Cancer Prostatic Dis. 2024. https:\/\/doi.org\/10.1038\/s41391-024-00920-1","DOI":"10.1038\/s41391-024-00920-1"},{"key":"1030_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41391-024-00898-w","volume":"28","author":"HY Hougen","year":"2025","unstructured":"Hougen HY, Reis IM, Han S, Prakash NS, Thomas J, Stoyanova R, et al. Evaluating 4Kscore\u2019s role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score. Prostate Cancer Prostatic Dis. 2025;28:180\u20136. https:\/\/doi.org\/10.1038\/s41391-024-00898-w.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1030_CR33","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41391-023-00675-1","volume":"26","author":"R Tutrone","year":"2023","unstructured":"Tutrone R, Lowentritt B, Neuman B, Donovan MJ, Hallmark E, Cole TJ, et al. ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer \u2013 an interim analysis. Prostate Cancer Prostatic Dis. 2023;26:596\u2013601. https:\/\/doi.org\/10.1038\/s41391-023-00675-1.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1030_CR34","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41391-024-00852-w)","volume":"27","author":"FB Denijs","year":"2024","unstructured":"Denijs FB, van Harten MJ, Meenderink JJL, Leenen RCA, Remmers S, Venderbos LDF, et al. Risk calculators for the detection of prostate cancer: a systematic review. Prostate Cancer Prostatic Dis. 2024;27:544\u201357. https:\/\/doi.org\/10.1038\/s41391-024-00852-w).","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1030_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41391-023-00665-3","volume":"26","author":"S Rais-Bahrami","year":"2023","unstructured":"Rais-Bahrami S, Zhu Y. Disparities in prostate cancer diagnosis and management: recognizing that disparities exist at all junctures along the prostate cancer journey. Prostate Cancer Prostatic Dis. 2023;26:441\u20132. https:\/\/doi.org\/10.1038\/s41391-023-00665-3.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1030_CR36","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.juro.2018.06.016","volume":"200","author":"NJ Sathianathen","year":"2018","unstructured":"Sathianathen NJ, Kuntz KM, Alarid-Escudero F, Lawrentschuk NL, Bolton DM, Murphy DG, et al. Incorporating biomarkers into the primary prostate biopsy setting: a cost-effectiveness analysis. J Urol. 2018;200:1215\u201320.","journal-title":"J Urol"},{"key":"1030_CR37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jval.2021.02.009","volume":"24","author":"B Jiao","year":"2021","unstructured":"Jiao B, Gulati R, Hendrix N, Gore JL, Rais-Bahrami S, Morgan TM, et al. Economic evaluation of urine-based or magnetic resonance imaging reflex tests in men with intermediate prostate-specific antigen levels in the United States. Value Health. 2021;24:1111\u20137.","journal-title":"Value Health"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01030-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01030-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01030-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:42:18Z","timestamp":1779331338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01030-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1030"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01030-2","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}